• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, January 27, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Scientists find antibody that blocks dengue virus

Bioengineer by Bioengineer
January 13, 2021
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Rajani Arora, University of Michigan Life Sciences Institute

A team of researchers led by the University of California, Berkeley and the University of Michigan has discovered an antibody that blocks the spread within the body of the dengue virus, a mosquito-borne pathogen that infects between 50 and 100 million people a year. The virus causes what is known as dengue fever, symptoms of which include fever, vomiting and muscle aches, and can lead to more serious illnesses, and even death.

“Protein structures determined at the APS have played a critical role in the development of drugs and vaccines for several diseases, and these new results are key to the development of a potentially effective treatment against flaviviruses.” — Bob Fischetti, group leader with Argonne’s X-ray Sciences Division and life sciences advisor to the APS director

Currently, there are no effective treatments or vaccines for the dengue virus. Since there are four different strains of the virus, building up antibodies against one strain can actually leave people more vulnerable to subsequent infection from another strain, which makes finding an effective therapeutic more difficult. Scientists using the Advanced Photon Source (APS), a U.S. Department of Energy (DOE) Office of Science User Facility located at the DOE’s Argonne National Laboratory, have reported success.

The dengue virus uses a particular protein, called Non-Structural Protein 1 (NS1), to latch onto the protective cells around organs. It weakens the protective barrier, allowing the virus to infect the cell, and may cause the rupture of blood vessels.  The research team’s antibody, called 2B7, physically blocks the NS1 protein, preventing it from attaching itself to cells and slowing the spread of the virus. Moreover, because it attacks the protein directly and not the virus particle itself, 2B7 is effective against all four strains of the dengue virus.

The research team used X-ray diffraction techniques to determine structures of the NS1 protein with a bound antibody (2B7) and showed how the antibody provides protection against the virus. These diffraction images were obtained at the General Medical Sciences and Cancer Institutes Structural Biology Facility (GM/CA) at the APS.

Researchers showed that the 2B7 antibody effectively blocks the spread of the dengue virus in live mice. They reported their results in Science. The paper suggests that this same antibody could provide new treatments for other flaviviruses like dengue, a group that includes Zika and West Nile.

“Flaviviruses infect hundreds of millions of people a year, and tens of thousands die from the associated diseases,” said Argonne’s Bob Fischetti, group leader with the X-ray Sciences Division and life sciences advisor to the APS director. “Protein structures determined at the APS have played a critical role in the development of drugs and vaccines for several diseases, and these new results are key to the development of a potentially effective treatment against flaviviruses.”

###

Read the University of Michigan press release.

About the Advanced Photon Source

The U. S. Department of Energy Office of Science’s Advanced Photon Source (APS) at Argonne National Laboratory is one of the world’s most productive X-ray light source facilities. The APS provides high-brightness X-ray beams to a diverse community of researchers in materials science, chemistry, condensed matter physics, the life and environmental sciences, and applied research. These X-rays are ideally suited for explorations of materials and biological structures; elemental distribution; chemical, magnetic, electronic states; and a wide range of technologically important engineering systems from batteries to fuel injector sprays, all of which are the foundations of our nation’s economic, technological, and physical well-being. Each year, more than 5,000 researchers use the APS to produce over 2,000 publications detailing impactful discoveries, and solve more vital biological protein structures than users of any other X-ray light source research facility. APS scientists and engineers innovate technology that is at the heart of advancing accelerator and light-source operations. This includes the insertion devices that produce extreme-brightness X-rays prized by researchers, lenses that focus the X-rays down to a few nanometers, instrumentation that maximizes the way the X-rays interact with samples being studied, and software that gathers and manages the massive quantity of data resulting from discovery research at the APS.

This research used resources of the Advanced Photon Source, a U.S. DOE Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation’s first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America’s scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC for the U.S. Department of Energy’s Office of Science.

The U.S. Department of Energy’s Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit https://energy.gov/science.

Media Contact
Beth Schlesinger
[email protected]

Original Source

https://www.anl.gov/article/scientists-find-antibody-that-blocks-dengue-virus

Related Journal Article

http://dx.doi.org/10.1126/science.abc0476

Tags: Medicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Ancient proteins help track early milk drinking in Africa

January 27, 2021
IMAGE

Pace of prehistoric human innovation could be revealed by ‘linguistic thermometer’

January 27, 2021

Partners in crime: genetic collaborator may influence severity of the rare disease, NGLY1

January 26, 2021

UC study: The dangers of drugged driving are outpacing drunk driving

January 26, 2021
Next Post
IMAGE

High-sensitivity nanophotonic sensors with passive trapping of analyte molecules in hot-spots

IMAGE

NIH scientists study salmonella swimming behavior as clues to infection

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    54 shares
    Share 22 Tweet 14
  • People living with HIV face premature heart disease and barriers to care

    69 shares
    Share 28 Tweet 17
  • New drug form may help treat osteoporosis, calcium-related disorders

    41 shares
    Share 16 Tweet 10
  • New findings help explain how COVID-19 overpowers the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Cell BiologyInfectious/Emerging DiseasescancerEcology/EnvironmentMedicine/HealthChemistry/Physics/Materials SciencesPublic HealthMaterialsTechnology/Engineering/Computer ScienceClimate ChangeGeneticsBiology

Recent Posts

  • Carbon-chomping soil bacteria may pose hidden climate risk
  • Ancient proteins help track early milk drinking in Africa
  • Genome-editing tool TALEN outperforms CRISPR-Cas9 in tightly packed DNA
  • Children can bypass age verification procedures in popular social media apps
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In